

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Statement of financial position**  
**as of 31 March 2026**

	31.03.2026	31.12.2025
<b>Non-current assets</b>	<i>EUR'000</i>	<i>EUR'000</i>
Property, plant and equipment	17 582	17 889
Intangible Assets and Goodwill	1 887	1 844
Trade receivables	2 603	2 603
<b>Non-current assets</b>	<b>22 072</b>	<b>22 336</b>
Inventories	9 635	9 165
Trade and other receivables	41 796	40 465
Cash and cash equivalents	101	607
<b>Current Assets</b>	<b>41 897</b>	<b>50 237</b>
<b>Assets</b>	<b>73 604</b>	<b>72 573</b>
Issued capital	49 033	49 033
Statutory reserve	7 525	7 525
Retained earnings	4 900	3 071
<b>Equity</b>	<b>61 458</b>	<b>59 629</b>
<i>Equity Attributable to owners of the parent company</i>	<i>61 458</i>	<i>59 629</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
Long term borrowings	665	789
Deferred tax liabilities	637	637
Non-current provisions for employee benefits	182	182
<b>Non-current liabilities</b>	<b>1 484</b>	<b>1 608</b>
Trade and other payables	5 604	5 590
Short term borrowings	4 459	5 228
Current tax liabilities	599	518
<b>Current liabilities</b>	<b>10 662</b>	<b>11 336</b>
<b>Liabilities</b>	<b>12 146</b>	<b>12 944</b>
<b>Equity and liabilities</b>	<b>73 604</b>	<b>72 573</b>

Date of preparation: 22.05.2026

Executive director:



Biser Georgiev

Prepared by:



Tsvetelina Pandeva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement of comprehensive income**  
**as of 31 March 2026**

	<b>31.03.2026</b>	<b>31.03.2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>
Revenue	9 619	8 259
Other income	2	42
<b>Total income</b>	<b>9 621</b>	<b>8 301</b>
Carrying amount of goods sold	(329)	(506)
Changes in inventories of finished products and work in progress	433	(148)
Materials and services	(5 813)	(4 581)
Personnel expenses	(1 407)	(1 326)
Depreciation / amortisation expenses	(382)	(361)
Other expenses	(106)	(87)
Finance income	5	6
Finance costs	(73)	(78)
<b>Total expenses</b>	<b>(7 672)</b>	<b>(7 081)</b>
<b>Profit Loss before tax</b>	<b>1 949</b>	<b>1 220</b>
Current tax expense income		
<b>Profit Loss</b>	<b>1 949</b>	<b>1 220</b>
<i>Profit Loss attributable to owners of the parent company</i>	(120)	(112)
<i>Profit Loss attributable to non-controlling interests</i>		
<b>Other comprehensive income</b>	<b>1 829</b>	<b>1 108</b>
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>	<b>1 829</b>	<b>1 108</b>
<b>Comprehensive income</b>		
<i>Profit Loss attributable to owners of the parent company</i>	<b>1 829</b>	<b>1 108</b>
<i>Profit Loss attributable to non-controlling interests</i>	-	-
Earnings per share / in EUR per 1 share /	0.02	0.01

Date of preparation: 22.05.2026

Executive director:



Biser Georgiev

Prepared by:



Tsvetelina Pandeva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Cash flow statement**  
**as of 31 March 2026**

	<b>31.03.2026</b>	<b>31.03.2025</b>
	<i>EUR'000</i>	<i>EUR'000</i>
<b>Cash flows from operating activities</b>		
Receipts from sales of goods and rendering of services	6 347	5 648
Payments to suppliers for goods and services	(3 174)	(2 907)
Payments to and on behalf of employees	(1 372)	(1 311)
Income taxes paid classified as operating activities	(120)	(112)
Other cash payments from operating activities	(1 183)	(995)
<b>Cash flows from used in operating activities</b>	<b>498</b>	<b>323</b>
 <b>Cash flows from investing activities</b>		
Purchase of other longterm assets classified as investing activities	(56)	(214)
<b>Cash flows from used in investing activities</b>	<b>(56)</b>	<b>(214)</b>
 <b>Cash flows from financial activities</b>		
Dividends paid classified as financing activities	40	60
Proceeds from borrowings classified as financing activities	(789)	(62)
Repayments of borrowings classified as financing activities	(47)	(60)
Payments of lease liabilities classified as financing activities	(152)	(67)
<b>Cash flows from used in financial activities</b>	<b>(948)</b>	<b>(129)</b>
 <b>Increase/Decrease in cash and cash equivalents</b>	<b>(506)</b>	<b>(20)</b>
<b>Cash and cash equivalents</b>	<b>607</b>	<b>40</b>
<b>Cash and cash equivalents</b>	<b>101</b>	<b>20</b>

Date of preparation: 22.05.2026

Executive director:

  
Biser Georgiev

Prepared by:

  
Tsvetelina Pandeva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement on changes in equity**  
**as of 31 March 2026**

	Issued capital <i>EUR'000</i>	Property plant and equipme nt revaluati on surplus <i>EUR'000</i>	Other reserves <i>EUR'000</i>	Retained earnings <i>EUR'000</i>	Equity abstract <i>EUR'000</i>	<i>Equity Attributab le to owners of the parent company EUR'000</i>	<i>Non- controllin g interest in equity EUR'000</i>
<b>Balance as of 01.01.2025</b>	<b>46 937</b>	<b>2 208</b>	<b>4 488</b>	<b>2 324</b>	<b>55 957</b>	<b>55 957</b>	-
Profit Loss				3 074	<b>3 074</b>	<b>3 074</b>	-
Other comprehensive income		598				<b>598</b>	-
<b>Comprehensive income</b>		<b>598</b>		<b>3 074</b>	<b>3 672</b>	<b>3 672</b>	-
Increase/Decrease through appropriation of retained earnings	2 096		231	(2 327)			
<b>Total income expense</b>	<b>2 096</b>		<b>231</b>	<b>(2 327)</b>			
<b>Balance as of 31.12.2025</b>	<b>49 033</b>	<b>2 806</b>	<b>4 719</b>	<b>3 071</b>	<b>59 629</b>	<b>59 629</b>	-
<b>Balance as of 01.01.2026</b>	<b>49 033</b>	<b>2 806</b>	<b>4 719</b>	<b>3 071</b>	<b>59 629</b>	<b>59 629</b>	-
Profit Loss				1 829	<b>1 829</b>	<b>1 829</b>	-
Other comprehensive income							-
<b>Comprehensive income</b>				<b>1 829</b>	<b>1 829</b>	<b>1 829</b>	-
Increase/Decrease through appropriation of retained earnings							-
<b>Total income expense</b>							-
<b>Balance as of 31.03.2026</b>	<b>49 033</b>	<b>2 806</b>	<b>4 719</b>	<b>4 900</b>	<b>61 458</b>	<b>61 458</b>	-

Date of preparation: 22.05.2026

Executive director:



Biser Georgiev

Prepared by:



Tsvetelina Pandeva